Please assess the completion status of the following clinical trial:

Trial Title: Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Subfertile premenopausal female patients eligible for in vitro fertilisation (IVF) treatment~* Aged ≥34 and ≤42 years~* Body mass index of \>18 and \<28 kg/m\^2~* Normal pelvic ultrasound at Screening~* No more than two previous gonadotrophin stimulated cycles of IVF or intracytoplasmic sperm injection (ICSI) in the history of infertility treatment (gonadotrophin stimulated cycles not used for IVF or ICSI do not count; Clomifen cycles are no exclusion criterion)~* At least 3 consecutive ovulatory menstrual cycles of 24-35 days~* No fertility stimulating drugs at all~* Sperm of partner classified as normal according to World Health Organisation (WHO) 2010 criteria~* Clinically normal baseline haematology, clinical chemistry, and urinalysis values~* Negative serum Hepatitis B Surface Antigen (HBsAg), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) antibody tests within the last 6 months prior to Screening~* Endocrine test results within the clinically normal limits at Screening~Exclusion Criteria:~* Presence of any clinically relevant systemic disease (e.g., insulin-dependent diabetes mellitus)~* A history of or current endocrine disease (excluding treated hypothyreosis), including polycystic ovary syndrome (PCOS) and hyperprolactinaemia~* A history of coagulation disorders~* Persistent ovarian cysts (\>3 months)~* A history of hypersensitivity to any of the constituents of the study medication or related compounds~* Diagnosed poor (\<3 oocytes) responders to prior gonadotrophin stimulated ART-cycle~* History of severe ovarian hyperstimulation syndrome in former gonadotrophin stimulated assisted reproductive technology (ART)-cycle

- Gender: FEMALE
- Minimum Age: 34 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Menotrophin (Type: EXPERIMENTAL): Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.
- Follitrophin Alpha (Type: ACTIVE_COMPARATOR): Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met. Pituitary down-regulation (cetrorelix), ovulation induction (choriongonadotropin), and luteal phase support (intravaginal progesterone) are administered the same way in both treatment arms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete